Chiesi agrees to acquire KalVista Pharmaceuticals for $1.9 billion. The deal marks the Italian company's largest acquisition to date, aimed at expanding its rare immunology portfolio.
Italian pharmaceutical company Chiesi has agreed to acquire US-listed KalVista Pharmaceuticals for approximately $1.9 billion to expand its rare immunology portfolio.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near United States
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
NextEra to pay $76/sh for Dominion: Bloomberg
NextEra to pay about $76 per share for Dominion, Bloomberg reports.
Global firms lose $25 billion in US-Israeli war with Iran, Reuters finds
The US-Israeli war with Iran has already cost companies around the world at least $25 billion — and the bill is climbing, according to a Reuters analysis
High energy prices could derail Europe’s AI race with U.S. and China - CNBC
High energy prices could derail Europe’s AI race with U.S. and China
Thai finance minister plans investment boost for economic recovery.
Thai finance minister signals plans to raise investment levels to bolster economic recovery.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.